human iduronate-2-sulfatase AAV gene therapy (NeuroGT)

N/A

Report date: 2025/06/11 11:11:34

Base Information

Drug Namehuman iduronate-2-sulfatase AAV gene therapy (NeuroGT)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionIduronate-2-sulfatase modulators
TargetsIduronate-2-sulfatase
Therapy Area/IndicationsMucopolysaccharidosis II
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNeuroGT Inc
China Registration ClassN/A

Develop Information

Active CompaniesNeuroGT Inc
Inactive CompaniesN/A
Active IndicationsMucopolysaccharidosis II
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A